LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial

BACKGROUND: Epidemiological data on obesity are needed, particularly in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular (CV) risk. We used the baseline data of liraglutide effect and action in diabetes: evaluation of CV outcome results—A long term Evaluation (LEADER) (a clinica...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Diabetol
Autors principals: Masmiquel, L., Leiter, L. A., Vidal, J., Bain, S., Petrie, J., Franek, E., Raz, I., Comlekci, A., Jacob, S., van Gaal, L., Baeres, F. M. M., Marso, S. P., Eriksson, M.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4750199/
https://ncbi.nlm.nih.gov/pubmed/26864124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-016-0341-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars